Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
View original at globenewswire.comVesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Vesicor is working to complete proposed de-SPAC merger with Blackhawk Acquisition Corporation and seeking to accelerate IND-enabling studies and IND-submission to the FDA
60% confidenceDr. Tolentino is an exceptional leader whose biotech industry expertise, deep relationships across the contract research organization (CRO) and pharma ecosystems and has a proven track record of creating shareholder value is exactly what Vesicor needs in its next CEO
60% confidenceVesicor does not have FDA approval for its sole product candidate and has not commenced FDA regulatory approval process as of the date of the press release
60% confidenceHas tremendous respect and admiration for Vesicor Therapeutics, its science and founders, and is eager to build upon the technology and work to position for IND submission in 2027
60% confidenceAikium with Avdarna is rapidly developing novel therapeutics replacing drugs going off patent with more efficacious, longer acting, less toxic, multi-specific and oral drugs
60% confidenceSees significant opportunities to develop potent therapeutics against cancer and create value for shareholders
60% confidence